Vimarsana
Biggest News Aggregation in the World

Page 48 - Medication Guide News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Medication Guide. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Medication Guide Today - Breaking & Trending Today

Idorsia Pharmaceuticals Ltd: Idorsia announces financial results for the first quarter 2023 - QUVIVIQ now the leading branded insomnia medicine in the commercial market in the US - Vimarsana News

Idorsia Pharmaceuticals Ltd: Idorsia announces financial results for the first quarter 2023 - QUVIVIQ now the leading branded insomnia medicine in the commercial market in the US

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland - April 25, 2023 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first quarter of 2023. Commercial highlights QUVIVIQ

SCOTUS Issues Stay - Vimarsana News

SCOTUS Issues Stay

/PRNewswire/ -- We at Danco are gratified the Supreme Court has granted a stay, which keeps the approval of Mifeprex intact without any changes. This stay is...

Axsome Therapeutics to Present Five Abstracts Including New Data from the Positive SHARP Study of SUNOSI® (solriamfetol) in Participants with Cognitive Impairment with Excessive Daytime Sleepiness in Obstructive Sleep Apnea at the 2023 American Academy of Neurology (AAN) Annual Meeting - Vimarsana News

Axsome Therapeutics to Present Five Abstracts Including New Data from the Positive SHARP Study of SUNOSI® (solriamfetol) in Participants with Cognitive Impairment with Excessive Daytime Sleepiness in Obstructive Sleep Apnea at the 2023 American Academy of Neurology (AAN) Annual Meeting

NEW YORK, April 21, 2023 -- Axsome Therapeutics, Inc. , a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system disorders, today... | April 21, 2023

Axsome Therapeutics to Present Five Abstracts Including New - Vimarsana News

Axsome Therapeutics to Present Five Abstracts Including New

NEW YORK, April 21, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel...

FDA Approves Genentech's Polivy in Combination With R-CHP for People With Certain Types of Previously Untreated Diffuse Large B-cell Lymphoma - Vimarsana News

FDA Approves Genentech's Polivy in Combination With R-CHP for People With Certain Types of Previously Untreated Diffuse Large B-cell Lymphoma

– Polivy combination is the first FDA-approved therapy in nearly 20 years for the first-line treatment of diffuse large B-cell lymphoma, an aggressive disease and the most common form of non-Hodgkin’s lymphoma in the U.S. –– POLARIX trial showed the Polivy combination reduced the risk of disease progression, relapse...